Subsequent Events |
9 Months Ended |
|---|---|
Apr. 30, 2026 | |
| Subsequent Events [Abstract] | |
| SUBSEQUENT EVENTS | NOTE 22 – SUBSEQUENT EVENTS
In June 2026, the Company announced that the last patient completed the final 96-week visit in its pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of NPC1. The Company expects to report topline results from the study in the second half of calendar 2026.
Additionally, the Company has completed a pre-New Drug Application (“NDA”) meeting with the U.S. Food and Drug Administration (“FDA”) and expects to submit an NDA for Trappsol® Cyclo™ in the second half of calendar 2026. |